Hepatitis C Virus: Efficacy of New DAAs Regimens

Author(s): Amal Ahmed Mohamed, Naglaa El-Toukhy Ramadan El-Toukhy, Ebada Mohamed Said, Hoda Mohamed Rabie Gabal, Hossameldin AbdelAziz, Wahid Doss, Hadeel El-Hanafi, Hala H. El Deeb, Seham Mahmoud, Mahmoud Elkadeem, Hassan Salama Shalby, Sherief Abd-Elsalam*.

Journal Name: Infectious Disorders - Drug Targets
(Formerly Current Drug Targets - Infectious Disorders)

Volume 20 , Issue 2 , 2020

Become EABM
Become Reviewer


Background: HCV treatment showed dramatical change due to the introduction of potent, strong, direct antiviral drugs. Before the appearance of Direct-acting antivirals, multiple therapeutic interventions were used for hepatitis C, but none of these interventions were effective on patient-centered outcomes. Direct-acting antivirals cause disruption of viral replication because they target specific nonstructural viral proteins.

Aim: To review the advantages of efficient HCV therapy and its long term drawbacks.

Methods: A search of the literature published in indexed databases (PubMed, Medline In-Process, and Embase) within the last 5 years was conducted. Any duplicated citations were excluded before first-pass screening. Citations (titles and abstracts) were screened for eligibility by a single reviewer. Full texts (including congress abstracts, posters and other congress communications) of citations deemed relevant during title and abstract screening were retrieved for second-pass review.

Results: Studies on the clinical effects of DAAs for hepatitis C show better tolerance, improved survival and fewer complications when compared to previous interferon therapy.

Conclusion: HCV treatment has improved dramatically. Since that time, there are multiple approved oral therapies all with high efficacy. The most important factor which should be considered during choosing appropriate therapy is to ensure that it covers the viral genotype of the infected patients.

Keywords: Direct-acting antivirals, HCV therapy, HCV treatment, sofosbuvir, interferon, DAA.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [143 - 149]
Pages: 7
DOI: 10.2174/1871526519666190121114003
Price: $65

Article Metrics

PDF: 14